Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2007

01-02-2007

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

Authors: Esther F. A. Brandon, Rolf W. Sparidans, Ronald D. van Ooijen, Irma Meijerman, Luis Lopez Lazaro, Ignacio Manzanares, Jos H. Beijnen, Jan H. M. Schellens

Published in: Investigational New Drugs | Issue 1/2007

Login to get access
Metadata
Title
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug
Authors
Esther F. A. Brandon
Rolf W. Sparidans
Ronald D. van Ooijen
Irma Meijerman
Luis Lopez Lazaro
Ignacio Manzanares
Jos H. Beijnen
Jan H. M. Schellens
Publication date
01-02-2007
Published in
Investigational New Drugs / Issue 1/2007
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-7589-7

Other articles of this Issue 1/2007

Investigational New Drugs 1/2007 Go to the issue

Preclinical Studies

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines

OriginalPaper

Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

Phase II Studies

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial

OriginalPaper

Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study

Phase II Studies

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

Phase II Studies

Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits